NCT07446751

Brief Summary

This prospective interventional study aims to evaluate the long-term refractive and visual quality outcomes of SMILE PRO surgery in patients with myopia and high astigmatism. Eligible participants undergo small incision lenticule extraction using the VisuMax 800 femtosecond laser. Postoperative assessments include uncorrected and corrected distance visual acuity, manifest refraction, astigmatic vector analysis, contrast sensitivity, and higher-order aberrations. Participants are followed for up to 12 months to assess refractive accuracy, stability, safety, and visual quality after surgery.

Trial Health

75
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
113

participants targeted

Target at P50-P75 for not_applicable

Timeline
2mo left

Started Dec 2024

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
active not recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress91%
Dec 2024Oct 2026

Study Start

First participant enrolled

December 10, 2024

Completed
1.2 years until next milestone

First Submitted

Initial submission to the registry

February 10, 2026

Completed
21 days until next milestone

First Posted

Study publicly available on registry

March 3, 2026

Completed
7 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 1, 2026

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

October 1, 2026

Last Updated

March 3, 2026

Status Verified

February 1, 2026

Enrollment Period

1.8 years

First QC Date

February 10, 2026

Last Update Submit

February 25, 2026

Conditions

Keywords

SMILE PROHigh astigmatismSmall incision lenticule extractionAstigmatic vector analysisCyclotorsionHigher-order aberrationsContrast sensitivity

Outcome Measures

Primary Outcomes (2)

  • Residual Refractive Astigmatism

    Residual refractive astigmatism was measured using manifest refraction and analyzed with astigmatic vector analysis based on the Alpins method.

    12 months postoperatively

  • Refractive Accuracy (Spherical Equivalent Error)

    Refractive accuracy was assessed using manifest refraction spherical equivalent (SEQ) after SMILE PRO surgery.

    12 months postoperatively

Secondary Outcomes (13)

  • Refractive Stability Over Time (Spherical Equivalent)

    1 week, 1 month, 3 months, 6 months, and 12 months postoperatively

  • Refractive Cylinder Over Time

    1 week, 1 month, 3 months, 6 months, and 12 months postoperatively

  • Uncorrected Distance Visual Acuity (UDVA)

    1 week, 1 month, 3 months, 6 months, and 12 months postoperatively

  • Corrected Distance Visual Acuity (CDVA)

    1 month, 3 months, 6 months, and 12 months postoperatively

  • Surgically Induced Astigmatism (SIA)

    3 months and 12 months postoperatively

  • +8 more secondary outcomes

Study Arms (1)

SMILE PRO surgery

EXPERIMENTAL

Participants with myopia and high astigmatism undergoing small incision lenticule extraction using the SMILE PRO surgery.

Procedure: SMILE PRO surgery

Interventions

Small incision lenticule extraction surgery performed using the VisuMax 800 femtosecond laser (SMILE PRO) for the correction of myopia with high astigmatism. The procedure is performed by a single experienced ophthalmic surgeon following a standardized surgical protocol.

SMILE PRO surgery

Eligibility Criteria

Age18 Years - 40 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • Patients aged 18 to 40 years at the time of surgery
  • Diagnosis of myopia with high astigmatism eligible for SMILE PRO surgery
  • Stable refractive error prior to surgery
  • Adequate corneal thickness and topographic parameters suitable for SMILE PRO
  • Ability to understand the study procedures and provide written informed consent
  • Willingness and ability to attend scheduled postoperative follow-up visits

You may not qualify if:

  • Presence of corneal ectatic disorders or suspicious corneal topography
  • History of previous ocular surgery or ocular trauma
  • Active ocular disease other than refractive error
  • Systemic diseases known to affect wound healing
  • Pregnancy or breastfeeding at the time of surgery

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Hong Son Eye Hospital

Hanoi, Hanoi, 100000, Vietnam

Location

Related Publications (4)

  • Reinstein DZ, Archer TJ, Potter JG, Gupta R, Wiltfang R. Refractive and Visual Outcomes of SMILE for Compound Myopic Astigmatism With the VISUMAX 800. J Refract Surg. 2023 May;39(5):294-301. doi: 10.3928/1081597X-20230301-02. Epub 2023 May 1.

    PMID: 37162399BACKGROUND
  • Pedersen IB, Ivarsen A, Hjortdal J. Changes in Astigmatism, Densitometry, and Aberrations After SMILE for Low to High Myopic Astigmatism: A 12-Month Prospective Study. J Refract Surg. 2017 Jan 1;33(1):11-17. doi: 10.3928/1081597X-20161006-04.

    PMID: 28068441BACKGROUND
  • Chan TCY, Wang Y, Ng ALK, Zhang J, Yu MCY, Jhanji V, Cheng GPM. Vector analysis of high (>/=3 diopters) astigmatism correction using small-incision lenticule extraction and laser in situ keratomileusis. J Cataract Refract Surg. 2018 Jul;44(7):802-810. doi: 10.1016/j.jcrs.2018.04.038. Epub 2018 Jun 13.

    PMID: 29909252BACKGROUND
  • Zhou J, Gu W, Gao Y, He G, Zhang F. Vector analysis of high astigmatism (>/= 2.0 diopters) correction after small-incision lenticule extraction with stringent head positioning and femtosecond laser-assisted laser in situ keratomileusis with compensation of cyclotorsion. BMC Ophthalmol. 2022 Apr 5;22(1):157. doi: 10.1186/s12886-022-02384-0.

    PMID: 35382779BACKGROUND

Study Officials

  • Lan Tran, MD

    Hanoi Medical University

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

February 10, 2026

First Posted

March 3, 2026

Study Start

December 10, 2024

Primary Completion (Estimated)

October 1, 2026

Study Completion (Estimated)

October 1, 2026

Last Updated

March 3, 2026

Record last verified: 2026-02

Data Sharing

IPD Sharing
Will share

De-identified individual participant data underlying the results reported in this study will be made available. Shared data will include demographic characteristics, preoperative and postoperative refractive outcomes, visual acuity measurements, astigmatic vector parameters, contrast sensitivity results, and wavefront-derived higher-order aberrations. No personally identifiable information will be shared.

Shared Documents
STUDY PROTOCOL, SAP
Time Frame
Data will be available beginning 12 months after publication of the primary results and will remain available for 5 years.
Access Criteria
Data will be shared with qualified researchers who submit a methodologically sound proposal. Requests will be reviewed by the study investigators, and data access will be granted after approval of the proposal and signing of a data use agreement.

Locations